Patients with genitourinary syndrome of menopause (GSM) who experience recurrent urinary tract infections require a targeted approach that addresses the underlying mucosal changes driving infection susceptibility. Evidence-based guidance exists specifically for this population.
Genitourinary syndrome of menopause co-occurring with recurrent urinary tract infections. The recurrent infections in this setting are recognised as a distinct clinical challenge linked to the genital and urinary tract changes of GSM.
Current evidence supports a locally applied vaginal intervention as the recommended first-line strategy to lower the risk of future infections in this population.
The complete regimen — including formulation, dosing, and duration — is available in the full structured protocol.
Meaningful reduction in the risk and frequency of recurrent urinary tract infections in patients with GSM.
In patients with GSM and recurrent urinary tract infections, clinicians should recommend local low-dose vaginal estrogen to reduce the risk for future urinary tract infections.
View source ↗